Never forget ocular syphilis: A case series from a single tertiary centre.
Seher KöksaldıArzu NazlıMahmut KayaAli Osman SaatciPublished in: International journal of STD & AIDS (2023)
A retrospective analysis of 10 consecutive patients who had serologically confirmed ocular syphilis between June 2020 and February 2023 was performed. All cases presented with ocular manifestations. Eight patients were diagnosed with syphilis and two patients with syphilis/human immunodeficiency virus co-infection. Type and duration of antibiotic treatments were diverse among the patients. Four patients had intramuscular benzyl-penicillin G 2.4 million units (MU) weekly for three weeks; four, intravenous ceftriaxone for 14 days; one, intravenous penicillin G 24 MU/day for 14 days; and the remaining patient, intravenous penicillin G 24 MU/day for a week and then oral doxycycline for two weeks. As adjunctive therapy to systemic antibiotics, oral corticosteroids in three patients and intravitreal ceftazidime (2.25 mg/0.1 mL) injections in one patient were administered. In conclusion, ocular syphilis is a re-emerging phenomenon; prompt diagnosis and proper antibiotic treatment can prevent serious ocular complications.
Keyphrases
- human immunodeficiency virus
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- hepatitis c virus
- randomized controlled trial
- clinical trial
- stem cells
- men who have sex with men
- high dose
- antiretroviral therapy
- hiv infected
- gram negative
- drug induced
- preterm birth
- hiv positive
- ultrasound guided
- optic nerve
- smoking cessation
- cell therapy
- combination therapy
- multidrug resistant